Metabolism of pyrimidine analogues and their nucleosides

George C. Daher, Barry E. Harris, Robert B Diasio

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

The pyrimidine antimetabolite drugs consist of base and nucleoside analogues of the naturally occurring pyrimidines uracil, thymine and cytosine. As is typical of antimetabolites, these drugs have a strong structural similarity to endogenous nucleic acid precursors. The structural differences are usually substitutions at one of the carbons in the pyrimidine ring itself or substitutions at one of the hydrogens attached to the ring of the pyrimidine or sugar (ribose or deoxyribose). Despite the differences noted above, these analogues, can still be taken up into cells and then metabolized via anabolic or catabolic pathways used by endogenous pyrimidines. Cytotoxicity results when the antimetabolite either is incorporated in place of the naturally pyrimidine metabolite into a key molecule (such as RNA or DNA) or competes with the naturally occurring pyrimidine metabolite for a critical enzyme. There are four pyrimidine antimetabolites that are currently used extensively in clinical oncology. These include the fluoropyrimidines, fluorouracil and fluorodeoxyuridine, and the cytosine analogues, cytosine arabinoside and azacytidine.

Original languageEnglish (US)
Pages (from-to)189-222
Number of pages34
JournalPharmacology and Therapeutics
Volume48
Issue number2
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Nucleosides
Antimetabolites
Pyrimidines
Cytosine
Nucleic Acid Precursors
Floxuridine
Deoxyribose
Azacitidine
Thymine
Ribose
Uracil
Medical Oncology
Cytarabine
Fluorouracil
Pharmaceutical Preparations
pyrimidine
Hydrogen
Carbon
RNA
DNA

ASJC Scopus subject areas

  • Pharmacology

Cite this

Metabolism of pyrimidine analogues and their nucleosides. / Daher, George C.; Harris, Barry E.; Diasio, Robert B.

In: Pharmacology and Therapeutics, Vol. 48, No. 2, 1990, p. 189-222.

Research output: Contribution to journalArticle

Daher, George C. ; Harris, Barry E. ; Diasio, Robert B. / Metabolism of pyrimidine analogues and their nucleosides. In: Pharmacology and Therapeutics. 1990 ; Vol. 48, No. 2. pp. 189-222.
@article{022ff640af6240bc876bfb1452cb9c59,
title = "Metabolism of pyrimidine analogues and their nucleosides",
abstract = "The pyrimidine antimetabolite drugs consist of base and nucleoside analogues of the naturally occurring pyrimidines uracil, thymine and cytosine. As is typical of antimetabolites, these drugs have a strong structural similarity to endogenous nucleic acid precursors. The structural differences are usually substitutions at one of the carbons in the pyrimidine ring itself or substitutions at one of the hydrogens attached to the ring of the pyrimidine or sugar (ribose or deoxyribose). Despite the differences noted above, these analogues, can still be taken up into cells and then metabolized via anabolic or catabolic pathways used by endogenous pyrimidines. Cytotoxicity results when the antimetabolite either is incorporated in place of the naturally pyrimidine metabolite into a key molecule (such as RNA or DNA) or competes with the naturally occurring pyrimidine metabolite for a critical enzyme. There are four pyrimidine antimetabolites that are currently used extensively in clinical oncology. These include the fluoropyrimidines, fluorouracil and fluorodeoxyuridine, and the cytosine analogues, cytosine arabinoside and azacytidine.",
author = "Daher, {George C.} and Harris, {Barry E.} and Diasio, {Robert B}",
year = "1990",
doi = "10.1016/0163-7258(90)90080-L",
language = "English (US)",
volume = "48",
pages = "189--222",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Metabolism of pyrimidine analogues and their nucleosides

AU - Daher, George C.

AU - Harris, Barry E.

AU - Diasio, Robert B

PY - 1990

Y1 - 1990

N2 - The pyrimidine antimetabolite drugs consist of base and nucleoside analogues of the naturally occurring pyrimidines uracil, thymine and cytosine. As is typical of antimetabolites, these drugs have a strong structural similarity to endogenous nucleic acid precursors. The structural differences are usually substitutions at one of the carbons in the pyrimidine ring itself or substitutions at one of the hydrogens attached to the ring of the pyrimidine or sugar (ribose or deoxyribose). Despite the differences noted above, these analogues, can still be taken up into cells and then metabolized via anabolic or catabolic pathways used by endogenous pyrimidines. Cytotoxicity results when the antimetabolite either is incorporated in place of the naturally pyrimidine metabolite into a key molecule (such as RNA or DNA) or competes with the naturally occurring pyrimidine metabolite for a critical enzyme. There are four pyrimidine antimetabolites that are currently used extensively in clinical oncology. These include the fluoropyrimidines, fluorouracil and fluorodeoxyuridine, and the cytosine analogues, cytosine arabinoside and azacytidine.

AB - The pyrimidine antimetabolite drugs consist of base and nucleoside analogues of the naturally occurring pyrimidines uracil, thymine and cytosine. As is typical of antimetabolites, these drugs have a strong structural similarity to endogenous nucleic acid precursors. The structural differences are usually substitutions at one of the carbons in the pyrimidine ring itself or substitutions at one of the hydrogens attached to the ring of the pyrimidine or sugar (ribose or deoxyribose). Despite the differences noted above, these analogues, can still be taken up into cells and then metabolized via anabolic or catabolic pathways used by endogenous pyrimidines. Cytotoxicity results when the antimetabolite either is incorporated in place of the naturally pyrimidine metabolite into a key molecule (such as RNA or DNA) or competes with the naturally occurring pyrimidine metabolite for a critical enzyme. There are four pyrimidine antimetabolites that are currently used extensively in clinical oncology. These include the fluoropyrimidines, fluorouracil and fluorodeoxyuridine, and the cytosine analogues, cytosine arabinoside and azacytidine.

UR - http://www.scopus.com/inward/record.url?scp=0025666730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025666730&partnerID=8YFLogxK

U2 - 10.1016/0163-7258(90)90080-L

DO - 10.1016/0163-7258(90)90080-L

M3 - Article

C2 - 2293239

AN - SCOPUS:0025666730

VL - 48

SP - 189

EP - 222

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 2

ER -